Introduction
============

Acute respiratory distress syndrome (ARDS) is typically caused by infections, such as pneumonia ([@ref-21]). Failure of timely and effective treatment will lead to multiple organ failure and death. Approximately 31% ([@ref-8]) of patients with ARDS are admitted to the intensive care unit (ICU), with a mortality rate of 19.7--57.7% ([@ref-2]; [@ref-3]; [@ref-8]). ARDS survivors are at greater risk of cognitive decline, depression, post-traumatic stress disorder, and persistent skeletal muscle weakness ([@ref-11]; [@ref-12]), bringing a great economic burden to families and society. Early pathogen identification and clinical intervention are critical for ARDS patients to reduce mortality and improve prognosis ([@ref-15]).

Conventional microbiological testing includes bacterial/fungal culture, polymerase chain reaction (PCR) nucleic acid hybridization, and serological antibody testing. The turn-around time of bacterial/fungal cultures is long (3--5 days), and the positive rate is low ([@ref-17]). PCR nucleic acid hybridization requires pre-screening of microbial pathogens and designing specific primers/probes, but detection types are limited ([@ref-23]). There is a window period that cannot be accurately identified by the serological antibody detection ([@ref-20]). Metagenome next-generation sequencing (mNGS) was first used to diagnose a central nervous system (CNS) infection of *Leptospira* in 2014 ([@ref-24]). This emerging diagnostic technology can quickly detect all nucleic acids in specimens of different sample types in one test, including blood, respiratory tract, CNS, and focal tissue ([@ref-9]; [@ref-10]; [@ref-16]; [@ref-17]). mNGS technology has been successfully used clinically for rapid identification of pathogens in ARDS patients with pneumonia ([@ref-7]) and can be used in clinical diagnosis and drug decision-making of severe pneumonia ([@ref-26]).

Different physiological indicators are crucial to the development and prognosis of ARDS in patients. Reduction of platelet count following ICU admission, age, body mass index, immunocompromised status, prone positioning, days of mechanical ventilation, disease score, elevated cardiac troponin T, extent of endothelial injury, low PaO~2~/FiO~2~ ratio, and different clinical intervention treatment options ([@ref-5]) affects the prognosis of patients with ARDS. Prior analysis of the prognosis of patients with ARDS using multiple Cox regression models found that late-onset moderate to severe ARDS was associated with adverse outcomes ([@ref-27]). However, the effect of mNGS technology on the prognosis of ARDS patients is unknown.

Currently, the clinical application of mNGS in ARDS appears predominantly in case reports or small-scale cohort studies. There is an urgent need to review the practical application of mNGS technology in ARDS patients, and assess its prognostic value. Thus, this study summarizes clinical information via retrospective analysis, and evaluates the clinical prognosis of ARDS by mNGS technology application.

Materials and Methods
=====================

Ethical approval and consent
----------------------------

The protocol used in this retrospective study was reviewed and approved by the Ethical Review Committee of Jiangmen Central Hospital (No: 2019-15). Patient's informed consent was obtained from patients or their next of kin.

Study participants
------------------

A retrospective analysis was conducted on all ARDS cases resulting from severe pneumonia in patients 18 years and older, admitted to the ICU at Jiangmen Central Hospital from January 2018 to August 2019. For our study, ARDS was diagnosed according to the 2012 Berlin definition of the disease ([@ref-1]). Patients were excluded from the study if their ARDS was not caused by severe pneumonia or if they did not follow through with their treatment for any reason.

All patients were endotracheally intubated, mechanically ventilated, and underwent a fiberoptic bronchoscopy to obtain clinical specimens for microbial testing. Patients were included in the next generation sequencing (NGS) group when informed consent was provided for testing; those who were not tested by mNGS were grouped into the no-NGS group. Owing to the cost of mNGS, only DNA sequencing was performed. Samples of bronchoalveolar lavage fluid (BALF) were acquired from patients in the NGS group and sent for pathogen testing at BGI Clinical Laboratories (Shenzhen) Co., Ltd. Once the laboratory received the samples, nucleic acid extraction, library construction, high-throughput sequencing, bioinformatics analysis, and pathogen data interpretation were performed according to previous studies ([@ref-17]).

Microbiological testing
-----------------------

Both groups were tested using the same conventional method (routine culture + serum antibody + PCR). The NGS group used mNGS + routine culture + serum antibody + PCR, while the no-NGS group used routine culture + serum antibody + PCR. Pathogenic microbes that cause severe pneumonia are typically bacteria, fungi, or viruses. Restricted by inspection conditions of the hospital, serum antibody and PCR nucleic acid detection could only detect some special pathogens and viruses that were clinically difficult to culture, as a supplement to routine culture. The serum antibody included *Mycoplasma pneumoniae, Chlamydia pneumoniae*, Coxsackie virus, cytomegalovirus, influenza A, influenza B, respiratory syncytial virus, and parainfluenza virus. PCR nucleic acids included *Legionella pneumophila, Mycoplasma pneumoniae, C. pneumoniae, Mycobacterium tuberculosis*, influenza A, and influenza B.

Clinical treatment
------------------

All patients underwent empirical antimicrobial treatment according to the Chinese Adult Community-Acquired Pneumonia Diagnosis and Treatment Guide ([@ref-4]) and the Chinese Adult Hospital-Acquired Pneumonia and Ventilator-associated Pneumonia Diagnosis Guide ([@ref-6]), combined with respiratory infection indicators and imaging. All patients were treated with mechanical ventilation according to the ARDS ventilation guidelines ([@ref-2]; [@ref-8]). The no-NGS patients were treated with an antimicrobial regimen based on the results of conventional microbiological tests. The antimicrobial regimen of NGS patients were adjusted case-by-case according to mNGS results.

Information collection and analysis
-----------------------------------

Patient data included age, gender, basic disease, laboratory test results before treatment, ventilator parameters, conventional microbiological tests, serum biomarkers, ICU special treatment data, APACHE II, and SOFA scores. Data were collected and compared between the two groups. The primary outcome was measured by a 28-day all-cause mortality. Secondary outcomes were measured as the length of stay in the ICU, duration of mechanical ventilation, duration of extracorporeal membrane oxygenation (ECMO), duration of prone ventilation positioning, and ICU treatment costs. Patients that showed signs of immunosuppression were selected from both groups and their prognosis compared using the same aforementioned outcomes. Cox regression analysis was conducted to analyze risk factors for ARDS prognosis. The mNGS results were compared with those of conventional microbiological tests in the NGS group.

Statistical analysis
--------------------

The *t*-test was used to determine normal distribution and uniformity of variance. The Wilcoxon rank test was used to calculate variance of measured data that were not normally distributed or had variance homogeneity. The chi-square test was used to calculate the difference between both groups. All statistical analyses were conducted using GraphPad 5.0 and R3.4.4 software. *P* \< 0.05 was considered statistically significant.

Results
=======

Sample and patient characteristics
----------------------------------

A total of 105 patients with ARDS caused by severe pneumonia were screened in this study and 10 patients were excluded based on exclusion criteria. Fourty two patients were placed into the NGS group and 53 patients in the no-NGS group. Three patients in the NGS group had two mNGS tests performed and a total of 45 BALF samples were sent for mNGS.

Patient demographics, characteristic baselines, and ICU special treatments in the NGS and no-NGS groups were shown in [Tables 1](#table-1){ref-type="table"}--[3](#table-3){ref-type="table"}, respectively. There were no significant differences in age, gender, basic disease, laboratory test results before treatment, ventilator parameters, APACHE II and SOFA scores before treatment, and incidences of special treatment in the ICU between both groups (*P* \> 0.05).

10.7717/peerj.9623/table-1

###### Patient characteristics and baseline of two groups.

![](peerj-08-9623-g006)

                                    NGS (*n* = 42)   no-NGS *(n* = 53)   *P*-value
  --------------------------------- ---------------- ------------------- -----------
  Age (yr)                                                               
  ≥ 60, *n* (%)                     21 (50.0)        33 (62.3)           0.231
  \< 60, *n* (%)                    21 (50.0)        20 (37.7)           
  Gender                                                                 
  Male, *n* (%)                     31 (73.8)        38 (71.7)           0.819
  Female, *n* (%)                   11 (26.2)        15 (28.3)           
  Basis disease                                                          
  Hypertension, *n* (%)             13 (31.0)        17 (32.1)           0.907
  Coronary heart disease, *n* (%)   3 (7.1)          5 (9.4)             0.690
  COPD, *n* (%)                     10 (23.8)        17 (32.1)           0.375
  Chronic nephrosis, *n* (%)        7 (16.7)         6 (11.3)            0.452
  Diabetes, *n* (%)                 5 (11.9)         9 (17.0)            0.488
  Immunosuppression, *n* (%)        8 (19.0)         13 (24.5)           0.523
  Tumor, *n* (%)                    10 (23.8)        11 (20.8)           0.722
  Smoking, *n* (%)                  20 (47.6)        17 (32.1)           0.123
  Drinking, *n* (%)                 4 (9.5)          5 (9.4)             0.988

**Notes:**

COPD, chronic obstructive pulmonary disease.

There were no any differences in age, sex ratio, basis disease between two groups (*P* \> 0.05).

The chi-square test was utilized to calculate the difference between the two groups.

*P* \< 0.05 was considered statistically significant.
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###### Laboratory examination before treatment, Ventilator parameters, APACHE II score and SOFA score before treatment of two groups.
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                                            NGS (*n* = 42)      no-NGS (*n* = 53)   *P*-value
  ----------------------------------------- ------------------- ------------------- -----------
  Laboratory examination before treatment                                           
  PCT (ug/L)                                1.3 (0.5, 8.4)      2.5 (0.3, 10.6)     0.516
  WBC (10^9^/L)                             10.5 (6.4, 15.4)    13.1 (7.5, 15.5)    0.189
  Hb (g/L)                                  109 (85, 130)       105 (84, 129)       0.932
  PLT (10^9^/L)                             159 (84, 205)       154 (112, 197)      0.780
  Scr (μmol/L)                              78 (64, 201)        97 (64, 121)        0.515
  T.Bil (mmol/L)                            11.8 (5.2, 17.2)    14.4 (7.8, 21.1)    0.071
  ALT (IU/L)                                28 (20, 47)         27 (20, 45)         0.612
  Alb (g/L)                                 28.0 (23.6, 31.6)   28.2 (24.8, 32.6)   0.880
  APTT (sec)                                35.6 (31.0, 44.7)   34.7 (26.4, 48.1)   0.614
  NT-proBNP (pg/ml)                         652 (236, 2747)     656 (311, 2066)     0.482
  Lac (mmol/L)                              1.6 (1.4, 2.9)      1.7 (1.2, 2.5)      0.763
  Ventilator parameters                                                             
  FiO~2~                                    0.8 (0.6, 1.0)      0.6 (0.5, 0.8)      0.992
  Peep                                      10 (8, 15)          8 (6, 12)           0.272
  OI                                        124 (76, 177)       156 (108, 194)      0.996
  APACHE II score before treatment          22 (18, 26)         21 (17, 26)         0.500
  SOFA score before treatment               7 (5, 8)            7 (4, 8)            0.875

**Notes:**

PCT, Procalcitonin; WBC, White blood cell; Hb, Hemoglobin; PLT, Platelet count; Scr, Serum creatinine; T.Bil, Total bilirubin; ALT, Alanine aminotransferase; Alb, Albumin; APTT, Activated partial thromboplastin time; NT-proBNP, N-terminal Pro-Brain Natriuretic Peptide; Lac, Lactate; FiO~2~, Fraction of inspiration O~2~; Peep, positive end-expiratory pressure; OI, Oxygenation Index; APACHE-II, Acute physiology and chronic health evaluation-II; SOFA, Sequential organ failure assessment.

There were no any differences in laboratory examination, ventilator parameters, APACHE II score and SOFA score before treatment between two groups (*P* \> 0.05).

The measured data of patients' physiological indicators in the above table were shown by median (interquartile range).

*P* \< 0.05 was considered statistically significant.

10.7717/peerj.9623/table-3

###### ICU special treatment of two groups.
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                                     NGS (*n* = 42)   no-NGS (*n* = 53)   *P*-value
  ---------------------------------- ---------------- ------------------- -----------
  Use of vasoactive agent, *n* (%)   24 (57.1)        30 (56.6)           0.958
  CRRT, *n* (%)                      9 (21.4)         7 (13.2)            0.288
  ECMO, *n* (%)                      6 (14.3)         3 (5.7)             0.177
  Prone positioning, *n* (%)         10 (23.8)        11 (20.8)           0.722

**Notes:**

ICU, intensive care unit; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation.

There were no any differences in ICU special treatment between two groups (*P* \> 0.05).

The chi-square test was utilized to calculate the difference between the two groups.

*P* \< 0.05 was considered statistically significant.

Comparison of outcomes between NGS and no-NGS groups
----------------------------------------------------

There was a significant difference in the 28-day all-cause mortality between both groups (*P* = 0.006) ([Table 4](#table-4){ref-type="table"}). The 28-day survival was significantly higher in the NGS group than in the no-NGS group (Hazard Ratio = 2.41, 95% CI: 1.21--4.17, *P* = 0.01) ([Fig. 1](#fig-1){ref-type="fig"}). There was no significant difference in the length of stay in the ICU, duration of mechanical ventilation, ECMO, prone position ventilation, or the cost of the ICU stay between both groups (*P* \> 0.05) ([Table 4](#table-4){ref-type="table"}).

![Analysis of 28-day survival curves of patients in the NGS group and the no-NGS group.\
The 28-day survival was significantly higher in the NGS group than in the no-NGS group (HR = 2.41, 95% CI: 1.21--4.17, *P* = 0.01).](peerj-08-9623-g001){#fig-1}
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###### Comparison of outcomes between NGS and no-NGS groups.

The primary outcome: There was a significant difference in 28-day all-cause mortality between the two groups (*P* = 0.006). The secondary outcome: There was no significant difference in the length of stay in the ICU, the duration of mechanical ventilation, ECMO, prone position ventilation, or the cost of the ICU stay between the two groups (*P* \> 0.05). The chi-square test was utilized to calculate the difference between the two groups in the primary outcome. The *t*-test was utilized to calculate the difference between the two groups in the secondary outcome. The measured data of patients' outcomes in the above table were shown by median (interquartile range).
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                                               NGS (*n* = 42)       no-NGS (*n* = 53)    *P*-value
  -------------------------------------------- -------------------- -------------------- ---------------------------------------
  The primary outcome                                                                    
  28-day all-cause mortality                   9 (21.4%)            26 (49.1%)           0.006[\*](#table-4fn1){ref-type="fn"}
  The secondary outcomes                                                                 
  Length of stay in ICU (days)                 12 (7, 20)           11 (8, 15)           0.719
  Duration of mechanical ventilation (h)       240 (144, 353)       216 (134, 311)       0.810
  Duration of ECMO (days)                      15 (11, 18)          10 (10, 23)          0.500
  Duration of prone position ventilation (h)   89 (63, 117)         96 (71, 121)         0.345
  Cost in ICU (thousand CNY)                   82.3 (55.1, 211.1)   98.9 (68.9, 141.1)   0.297

**Note:**

*P* \< 0.05 was considered statistically significant.

Prognosis of ARDS patients
--------------------------

Cox univariate analysis was performed on all factors and Cox multivariate analysis was performed with variates which were *P* \< 0.2 of the Cox univariate analysis ([Table S1](#supp-2){ref-type="supplementary-material"}). The NGS or no-NGS group, length of stay in ICU, and APACHE II and SOFA scores before treatment were risk factors in patients with ARDS caused by severe pneumonia. The NGS group patients had a better prognosis than that of the no-NGS group patients (*P* = 0.005). A shorter stay in the ICU (*P* = 0.037), and lower APACHE II (*P* = 0.016) and SOFA scores before treatment (*P* = 0.003) had a better prognosis ([Table 5](#table-5){ref-type="table"}).
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###### Cox multivariate analysis of prognosis of patients with ARDS.

The NGS group had a better prognosis than no-NGS group (*P* = 0.005). Those with a shorter stay in the ICU (*P* = 0.037), and lower APACHE II before treatment (*P* = 0.016) and SOFA scores before treatment (*P* = 0.003) had a better prognosis.
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                                     HR      Lower .95   Upper .95   *P*-value
  ---------------------------------- ------- ----------- ----------- ---------------------------------------
  mNGS (yes/no)                      0.263   0.105       0.663       0.005[\*](#table-5fn1){ref-type="fn"}
  Age (years)                        1.013   0.988       1.038       0.322
  Length of stay in ICU (days)       0.888   0.794       0.993       0.037[\*](#table-5fn1){ref-type="fn"}
  APACHE II score before treatment   1.112   1.020       1.212       0.016[\*](#table-5fn1){ref-type="fn"}
  SOFA score before treatment        1.339   1.105       1.622       0.003[\*](#table-5fn1){ref-type="fn"}
  Coronary heart disease (yes/no)    1.660   0.556       4.958       0.364
  Bronchiectasis (yes/no)            1.128   0.331       3.843       0.848
  Diabetes (yes/no)                  0.324   0.088       1.195       0.091
  Hb (g/L)                           0.993   0.980       1.006       0.284
  T.Bil (mmol/L)                     0.999   0.987       1.012       0.882
  Be                                 1.063   0.996       1.133       0.064
  Use of vasoactive agent (yes/no)   1.443   0.587       3.548       0.424
  ECMO (yes/no)                      1.212   0.067       21.764      0.896
  Cost in ICU (CNY)                  1.000   1.000       1.000       0.477

**Note:**

*P* \< 0.05 was considered statistically significant.

Comparison of mNGS results and culture results in the NGS group
---------------------------------------------------------------

The current research showed that the mNGS test can detect more pathogens than the culture method. We analyzed the consistency of pathogens identified by both techniques. The test results were considered to be consistent when the pathogens identified by mNGS were the same as the pathogens obtained from culture. The test results were also considered consistent if mNGS identified more pathogens than the culture method. The result was partially consistent when pathogens identified by both methods were partially congruent. The results were considered inconsistent when pathogens identified by both methods varied completely. Identified pathogens (31.1%) in the NGS group were consistent, 15.6% were partially consistent, and 53.3% were completely inconsistent. In the inconsistent ones, 62.5% were negative for the culture method, while 8.3% were negative for mNGS, and 29.2% were mismatched ([Fig. 2](#fig-2){ref-type="fig"}).

![The consistent analysis comparing culture and mNGS pathogen detection in the NGS group.\
Identified pathogens (31.1%) in the NGS group were consistent, 15.6% were partially consistent, and 53.3% were completely inconsistent. In the inconsistent ones, 62.5% were negative for the culture method, while 8.3% were negative for mNGS, and 29.2% were mismatched.](peerj-08-9623-g002){#fig-2}

Comparison metagenomic of NGS results and conventional microbiological tests
----------------------------------------------------------------------------

Some special pathogens were difficult to obtain via culture. Therefore, *Legionella*, *Tuberculosis*, *Mycoplasma*/*Chlamydia*, parasites, K. spores, *etc*. were defined as such. Severe pneumonia is not caused by a single pathogen and is typically accompanied by co-infections. A co-infection is defined as a non-single pathogenic infection, such as bacteria + fungi/bacteria + virus/fungi + virus/bacteria + fungi + virus.

The positive rate of mNGS virus detection was lower than that of serum antibody detection plus PCR (6.7% vs. 26.7%, *P* = 0.021). In this study, mNGS only performed DNA sequencing and could only detect DNA viruses, whereas viruses identified by serological antibody detection and PCR were RNA viruses, such as influenza A and influenza B. mNGS was significantly better at detecting bacteria than serological antibody testing plus PCR (24.4% vs. 0%, *P* = 0.001). Further, mNGS was able to detect specific pathogens better than the culture method (22.2% vs. 0%, *P* = 0.001) and serological antibody testing plus PCR (22.2% vs. 2.2%, *P* = 0.007). Additionally, mNGS was significantly better at the identification of co-infections than serological antibody tests plus PCR (26.7% vs. 0%, *P* \< 0.001). Finally, mNGS proved to be significantly better at identifying pathogens than the culture method (91.1% vs. 62.2%, *P* = 0.001) and serological antibody testing plus PCR (91.1% vs. 28.9%, *P* \< 0.001) ([Table 6](#table-6){ref-type="table"}).
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###### Comparison of metagenomic NGS results and conventional microbiological tests.

The positive rate of mNGS virus detection was lower than that of serum antibody detection plus PCR (6.7% vs. 26.7%, *P* = 0.021). mNGS was significantly better at detecting bacteria than serological antibody testing plus PCR (24.4% vs. 0%, *P* = 0.001). Further, mNGS was able to detect specific pathogens better than the culture method (22.2% vs. 0%, *P* = 0.001) and serological antibody testing plus PCR (22.2% vs. 2.2%, *P* = 0.007). Additionally, mNGS was significantly better at the identification of co-infections than serological antibody tests plus PCR (26.7% vs. 0%, *P* \< 0.001). Finally, mNGS proved to be significantly better at identifying pathogens than the culture method (91.1% vs. 62.2%, *P* = 0.001) and serological antibody testing plus PCR (91.1% vs. 28.9%, *P* \< 0.001).
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                              Method A (*n* = 45)   Method B (*n* = 45)   Method C (*n* = 45)   *P*-value,\                             *P*-value,\
                                                                                                A vs. B                                 A vs. C
  --------------------------- --------------------- --------------------- --------------------- --------------------------------------- -----------------------------------------
  Only virus, *n* (%)         3 (6.7)               0 (0.0)               12 (26.7)             0.24                                    0.021[\*](#table-6fn3){ref-type="fn"}

  Only bacterial, *n* (%)     11 (24.4)             15 (33.3)             0 (0.0)               0.486                                   0.001[\*](#table-6fn3){ref-type="fn"}

  Only fungus, *n* (%)        5 (11.1)              5 (50.0)              0 (0.0)               1                                       0.056

  Special pathogen, *n* (%)   10 (22.2)             0 (0.0)               1 (2.2)               0.001[\*](#table-6fn3){ref-type="fn"}   0.007[\*](#table-6fn3){ref-type="fn"}

  Co-infection, *n* (%)       12 (26.7)             8 (17.8)              0 (0.0)               0.311                                   \<0.001[\*](#table-6fn3){ref-type="fn"}

  Overall positive, *n* (%)   41 (91.1)             28 (62.2)             13 (28.9)             0.001[\*](#table-6fn3){ref-type="fn"}   \<0.001[\*](#table-6fn3){ref-type="fn"}
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Method A: mNGS; Method B: Culture; Method C: Serological antibody test plus PCR.

The Chi-square test was utilized to calculate the difference between the two groups.

*P* \< 0.05 was considered statistically significant.

Clinical medication guidance between NGS and no-NGS groups
----------------------------------------------------------

In the NGS group, 30 patients (71.4%) did not cover all the microbial detected by mNGS in the initial empirical antimicrobial treatment. Thus, antimicrobial regimen needs to be modified accordingly based on the mNGS results. In the no-NGS group, empirical antimicrobial treatment that could not cover the detected microbials was found in 23 patients (43.4%), according to the results of traditional microbiological testing, and they were necessary to adjust the anti-infection program ([Fig. 3](#fig-3){ref-type="fig"}). Following adjustment of the anti-infective regimen, we continuously observed APACHE II and SOFA scores for both groups of patients for 7 days and found that the NGS group had a lower APACHE II score than the no-NGS group, 7 days after treatment (*P* = 0.041) ([Fig. 4](#fig-4){ref-type="fig"}).

![Coverage spectrum of empirical antimicrobial therapy for pathogen detection results in two groups.\
(A) In the NGS group, 30 patients (71.4%) did not cover all the microbial detected by mNGS in the initial empirical antimicrobial treatment. Thus, antimicrobial regimen needs to be modified accordingly based on the mNGS results. (B) In the no-NGS group, empirical antimicrobial treatment that could not cover the detected microbials was found in 23 patients (43.4%), according to the results of traditional microbiological testing, and they were necessary to adjust the anti-infection program.](peerj-08-9623-g003){#fig-3}

![APACHE II and SOFA scores of the two groups.\
(A) The NGS group had a lower APACHE II score than that in the no-NGS group after 7 days of treatment (*P* = 0.041). (B) There was no significant difference in SOFA score during 7 days between two groups (*P* \> 0.05).](peerj-08-9623-g004){#fig-4}

Immunosuppressed patients
-------------------------

Clinical features of immunosuppressed patients were complicated. A total of 21 immunosuppressed patients were enrolled in our study, eight were subjected to mNGS pathogen detection, and 13 did not undergo mNGS. Three cultures were positive in the NGS group, consistent with pathogens identified by mNGS, including five *Pneumocystis jirovecii*, one *Rhizopus*, one *Cryptococcus*, and one human herpesvirus; six were co-infections.

In the no-NGS group, nine cases were positive for culture, and two *Stenotrophomonas maltophilia*, two *Acinetobacter baumannii*, one *Staphylococcus aureus*, four *Candida*, and one *Aspergillus* were detected. Four cases had multi-drug resistant bacteria. There was no significant difference in the 28-day all-cause mortality between the two groups (37.5% vs. 53.8%, *P* = 0.659). However, there were significant differences in the length of stay in the ICU (*P* = 0.023), duration of mechanical ventilation (*P* = 0.030), and cost of the stay in the ICU (*P* = 0.004) between both groups of immunosuppressed patients ([Fig. 5](#fig-5){ref-type="fig"}).

![Clinical data of 21 immunosuppressed patients with NGS and no-NGS were compared.\
The NGS group had shorter length of stay in the ICU (A) (*P* = 0.023), shorter ventilation time (B) (*P* = 0.030), and less cost in ICU (C) (*P* = 0.004) than those in the no-NGS group of immunosuppressed patients.](peerj-08-9623-g005){#fig-5}

Discussion
==========

Acute respiratory distress syndrome caused by severe pneumonia is critical and progresses rapidly. Common microbial infection includes those of bacteria, fungi, and viruses while some are co-infections ([@ref-15]). Patients usually require broad-spectrum anti-infection treatment, and then, further adjust to targeted anti-infection treatment based on microbial detection results of. Therefore, it is critical to determine the type of microbial infection for ARDS treatment caused by severe pneumonia.

This study compared the effectiveness of mNGS with traditional microbiological testing methods of the NGS group. Firstly, mNGS was faster, taking an average of 2 days from sending samples to receiving reports, whereas routine culture requires at least 3--5 days. Secondly, the overall positive rate (91.1%) of mNGS was significantly higher than that of culture (62.2%, *P* = 0.001) and antibody plus PCR (28.9%, *P* \< 0.001). As all patients included were diagnosed with severe pneumonia, the positive rate of mNGS and culture of lower respiratory tract specimens were higher than that of usual detection. Thirdly, the positive rate of mNGS detection of specific pathogens (22.2%) was higher than that of culture (0%, *P* = 0.001) and antibody plus PCR (2.2%, *P* = 0.007). This conclusion was consistent with a previous study by [@ref-19] in that the positive of mNGS was much higher than that of culture, and rare pathogens could be detected. In addition, we analyzed the consistency between mNGS and culture, 31.1% of identified pathogens in the NGS group were consistent, 15.6% were partially consistent, and 53.3% were completely inconsistent. In the inconsistent ones, 62.5% were negative for culture, while only 8.3% were negative for mNGS. The advantages of mNGS detection compared with traditional detection were confirmed.

By comparing the prognosis of patients between the NGS group and the no-NGS group, it was found that the 28-day mortality rate of the NGS group was significantly lower than that of the no-NGS group (*P* \< 0.05) ([Table 4](#table-4){ref-type="table"}). There was no difference in ICU hospitalization time, mechanical ventilation time, ECMO time, prone position ventilation time, and ICU treatment costs between the two groups ([Table 4](#table-4){ref-type="table"}). This conclusion was consistent with the study of [@ref-25]. They analyzed 178 patients with severe pneumonia and combined mNGS results to guide treatment. The 28-day and 90-day survival rates of severe pneumonia patients were improved. The 90-day survival rate increased from 57.7% to 83.3%.

In this study, clinicians assisted clinical diagnosis through comprehensive microbial testing; the empirical medication of 71.4% of patients in the NGS group did not cover clinically diagnosed microbial infections, whose anti-infection treatment should be adjusted based on mNGS results. In the no-NGS group, 43.4% of patients required adjustment of the empirical anti-infection regimen. Due to faster and more effective adjustment of the anti-infection regimen, it was found that APACHE II scores in the NGS group were lower than those in the no-NGS group 7 days after treatment (*P* = 0.041, [Fig. 4](#fig-4){ref-type="fig"}). This means that the mNGS test results have a positive effect on clinical medication guidance. Moreover, a multiple Cox regression analysis was conducted for assessment of prognostic factors and found that a longer stay in ICU, high APACHE II score, and high SOFA score were risk factors for ARDS death, and the application of mNGS for clinical pathogen detection was a protective factor. It was shown that the higher the APACHE II and SOFA scores of sepsis patients, the worse the prognosis ([@ref-13]; [@ref-14]), which is consistent with our results.

In addition, studies have shown that immunosuppressed patients were prone to co-infection. mNGS technology has distinct advantages in detecting co-infection pathogens ([@ref-18]). In this study, mNGS detected specific pathogens that were difficult to culture in immunosuppressed patients, including *Pneumocystis*, *Rhizopus*, *Cryptococcus*, and viruses. Although the mortality rate of the NGS group was lower than that of the no-NGS group, the difference in the prognostic analysis of immunosuppressed patients was not statistically significant (37.5% vs. 53.8%, *P* = 0.659), and may be related to the small sample size. Moreover, we found that mNGS technology can significantly shorten the length of stay in the ICU of immunosuppressed patients, shorten the ventilation time, and reduce the cost in ICU (*P* \< 0.05). From the economics and clinical prognosis, immunosuppressed patients were more suitable for mNGS technology application in the early clinical stage to assist clinical diagnosis and drug decision-making.

Limitations to the use of mNGS technology exist, despite its widespread use. There is no authoritative guide to the interpretation of the mNGS report. Detection of a broad spectrum of pathogens by mNGS has blunted the diagnosis of pathogenicity resulting in the inability to distinguish between background, colonization and microbial infection, and pollution ([@ref-22]). Better technology needs to be developed for mNGS to be used successfully in clinical applications. The use of mNGS in clinical applications will: (1) achieve a faster diagnosis of pathogens and obtain information on drug resistance of related pathogens; (2) identify microbial colonization or infection through monitoring the patient's immune response, which will eventually curb bacterial resistance, achieve a rational application of antibiotics, and ultimately reduce the economic and social burden of infectious diseases; (3) lower the cost of the mNGS test with the development of technology, so that more patients will benefit.

Our research also has certain limitations. Firstly, our mNGS only performed DNA sequencing and did not perform RNA sequencing; therefore, the information of RNA virus and microbial transcriptome alterations were missing, resulting in the positive rate of mNGS virus detection being lower than serum antibody plus PCR (6.7% vs. 26.7%, *P* = 0.021). Secondly, restricted by the inspection conditions of the hospital, PCR detection only included some RNA viruses, such as influenza A and influenza B. Additionally, the prognostic analysis was affected by several clinical factors and sample size of this study was not large, resulting in some data inconsistency. For example, the mortality rate between the two groups was significantly different, but that of the immunosuppressed patients was not. There was no difference in ICU stay, cost, and ventilation time between the two groups, but there was a difference between the two groups of immunosuppressed patients.

Conclusions
===========

Metagenome next-generation sequencing technology is valuable for the diagnosis, treatment and prognosis of ARDS caused by severe pneumonia. mNGS technology is superior to conventional microbiological tests for the detection of special pathogens and co-infections. mNGS technology harbors great potential for clinical infection. Further research should include a larger sample size, involving multi-center, prospective, and controlled studies, which will help us better understand the clinical experience summary and prognostic value of mNGS detection in ARDS caused by severe pneumonia.
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